BridgeMD
New treatment option for Corneal Neovascularisation
Official title Fine-needle Diathermy Combined With Subconjunctival Bevacizumab for Corneal Neovascularization
ClinicalTrials.gov ID: NCT07642960
What this study is testing
What is Bevacizumab?
Bevacizumab is an investigational medicine, given as a treatment applied to the skin, being studied as a potential treatment for corneal neovascularisation.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to evaluate the efficacy and safety of combined fine-needle diathermy and subconjunctival Bevacizumab injection in patients with corneal neovascularization. The main questions it aims to answer are: Does combined fine-needle diathermy and subconjunctival Bevacizumab injection promote regression of corneal neovascularization?
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age over 18 years.
- Diagnosis of corneal neovascularization involving at least one quadrant of the cornea, confirmed by slit-lamp examination.
- Corneal neovascularization is stable with no evidence of progression for at least 4 weeks.
- Agreement to participate in the study and ability to comply with outpatient follow-up requirements
You likely can't join if
- Pregnant or breastfeeding women.
- History of hypersensitivity or allergy to bevacizumab or any component of the study medication.
- Presence of severe systemic disease that would preclude study participation or surgical intervention, including coagulation disorders or uncontrolled...
- Active ocular infection or acute conjunctivitis at the time of enrollment.
- Persistent corneal epithelial defect or delayed corneal epithelial healing.
- History of ocular surgery within 3 months before study enrollment.
See the full eligibility criteria
- Age over 18 years.
- Diagnosis of corneal neovascularization involving at least one quadrant of the cornea, confirmed by slit-lamp examination.
- Corneal neovascularization is stable with no evidence of progression for at least 4 weeks.
- Agreement to participate in the study and ability to comply with outpatient follow-up requirements
- Pregnant or breastfeeding women.
- History of hypersensitivity or allergy to bevacizumab or any component of the study medication.
- Presence of severe systemic disease that would preclude study participation or surgical intervention, including coagulation disorders or uncontrolled cardiovascular disease.
- Active ocular infection or acute conjunctivitis at the time of enrollment.
- Persistent corneal epithelial defect or delayed corneal epithelial healing.
- History of ocular surgery within 3 months before study enrollment.
- Corneal neovascularization associated with uncontrolled secondary glaucoma.
- Inability or unwillingness to comply with study treatment or follow-up visits.
The study team makes the final eligibility decision.
Where it's taking place
- Ho Chi Minh City, Xuan Hoa, Vietnam
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Ho Chi Minh City, Xuan Hoa, Vietnam. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.